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Abstract
Summary This post-hoc analysis queried whether women experiencing fracture on denosumab indicates inadequate
treatment response or whether the risk of subsequent fracture remains low with continuing denosumab. Results showed
that denosumab decreases the risk of subsequent fracture and fracture sustained while on denosumab is not necessarily
indicative of inadequate treatment response.
Introduction This analysis assessed whether a fracture sustained during denosumab therapy indicates inadequate treat-
ment response and if the risk of a subsequent fracture decreases with continuing denosumab treatment.
Methods In FREEDOM, a clinical trial to evaluate the efficacy and safety of denosumab, postmenopausal women with
osteoporosis were randomized to placebo or denosumab for 3 years. In the 7-year FREEDOM Extension, all participants
were allocated to receive denosumab. Here we compare subsequent osteoporotic fracture rates between denosumab-
treated subjects during FREEDOM or the Extension and placebo-treated subjects in FREEDOM.
Results During FREEDOM, 438 placebo- and 272 denosumab-treated subjects had an osteoporotic fracture.
Exposure-adjusted subject incidence per 100 subject-years was lower for denosumab (6.7) vs placebo (10.1).
Combining all subjects on denosumab from FREEDOM and the Extension for up to 10 years (combined
denosumab), 794 (13.7%) had an osteoporotic fracture while on denosumab. Of these, one or more subsequent
fractures occurred in 144 (18.1%) subjects, with an exposure-adjusted incidence of 5.8 per 100 subject-years, similar
to FREEDOM denosumab (6.7 per 100 subject-years) and lower than FREEDOM placebo (10.1 per 100 subject-
years). Adjusting for prior fracture, the risk of having a subsequent on-study osteoporotic fracture was lower in the
combined denosumab group vs placebo (hazard ratio [95% CI]: 0.59 [0.43–0.81]; P = 0.0012).
Conclusions These data demonstrate that denosumab decreases the risk of subsequent fracture and a fracture sustained
while on denosumab is not necessarily indicative of inadequate treatment response.
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Introduction
Although osteoporosis therapy decreases fracture risk,
fracture can occur while on treatment but not necessar-
ily representing an inadequate response to therapy. In
appropriately selected subjects, approved osteoporosis
medications reduce, but do not eliminate, the risk of
fracture. Clinical trials of efficacious therapeutic agents
invariably report fractures in subjects receiving active
drug, as well as those receiving placebo [1–4].
Furthermore, it is also recognized that in treatment-
naïve subjects (and also likely in subjects on therapy)
a new fragility fracture greatly increases the risk of
subsequent fracture [5, 6]. It is therefore expected that
some fractures will occur in subjects receiving treatment
for osteoporosis, similar to what is observed in other
diseases, such as hypertension and hypercholesterolemia,
where treatment decreases, but does not eliminate, the
risk of major adverse cardiac events [7, 8].
It has been suggested that the occurrence of at least two
incident fractures and/or reductions in bone mineral den-
sity (BMD) greater than the least significant change while
receiving treatment for osteoporosis are evidence of an
inadequate response to therapy [9–11]. In addition, inad-
equate response should also be considered in subjects who
sustained only one fracture while bone markers and BMD
have not responded as expected for a given treatment.
Circumstances that might contribute to an inadequate re-
sponse to therapy include an unrecognized secondary
cause of skeletal fragility, poor adherence to therapy, mal-
absorption, vitamin D deficiency, or inadequate efficacy
of the chosen treatment. However, fractures may occur
despite effective treatment, since any bone will fracture
when it is exposed to sufficient force.
In the Fracture REduction Evaluation of Denosumab in
Osteoporosis every 6 Months (FREEDOM) study, an interna-
tional, randomized, placebo-controlled 3-year trial, denosumab
reduced the risk of new vertebral, nonvertebral, and hip frac-
tures in postmenopausal women with osteoporosis [4]. In the
FREEDOM Extension study, eligible women received
denosumab therapy for up to 10 years, and fracture incidence
remained low after up to 10 years of treatment [12–16].
In this analysis, we tested the hypothesis that women who
fractured while on denosumab treatment had a lower risk of
subsequent fracture while continuing on therapy compared
with women who received placebo.
Materials and methods
Study design
This analysis is based on a placebo-controlled trial and its open-
label extension. The first was FREEDOM, an international,
multicenter, randomized, double-blind, placebo-controlled
study that has been previously described (Fig. 1) [4, 12]. In this
study, eligible women were postmenopausal, 60–90 years old,
with a lumbar spine or total hip BMD T-score less than − 2.5 at
either site, but greater than or equal to − 4.0 at both locations.
Eligible women could not have had any severe, or more than
two moderate, vertebral fractures and were free of other sec-
ondary causes of bone loss. Randomization was 1:1 to subcu-
taneous placebo or 60 mg denosumab (Prolia®; Amgen Inc.,
Thousand Oaks, CA, USA) every 6 months for 3 years, with
daily calcium (≥ 1 g) and vitamin D (≥ 400 IU) supplements.
The second study, FREEDOM Extension, has also been
previously described [16]. Eligible subjects for the
Extension were women who completed the FREEDOM study
3-year visit and did not discontinue or miss more than one
dose of investigational product in either the denosumab or
placebo arm. In the Extension, all participants were scheduled
to receive subcutaneous open-label 60 mg denosumab every
6 months (± 1 month) with daily calcium and vitamin D. The
Extension duration was for up to 7 years, for a total of up to
10 years of denosumab treatment from the start of the
FREEDOM study.
This post-hoc analysis compared subsequent osteoporotic
fracture rates between women receiving denosumab during
FREEDOM or the Extension with women receiving placebo
during FREEDOM. Subsequent osteoporotic fracture was de-
fined as a new vertebral fracture (including both radiographic
and clinical vertebral fractures) or nonvertebral fracture that
occurred after an initial on-study fracture in subjects who re-
ceived at least two doses of investigational product (placebo or
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Fig. 1 FREEDOM and FREEDOM Extension study design. This
analysis included women who had received ≥ 2 doses of investigational
product (placebo or denosumab) during FREEDOM or the Extension,
had an osteoporotic fracture (new vertebral, including clinical vertebral,
or nonvertebral) while on treatment, and continued treatment post-
fracture. Q6M = every 6 months; SC = subcutaneously
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denosumab) during FREEDOM or two doses of denosumab
during the Extension and who continued treatment post-frac-
ture. Participants were evaluated in three groups: FREEDOM
placebo, FREEDOM denosumab, and combined denosumab.
The combined denosumab group included subjects from the
FREEDOM trial who received denosumab, subjects from the
Extension long-term group who received denosumab, and sub-
jects from the Extension crossover group who switched to
denosumab during the Extension. Multiple confirmed frac-
tures with the same x-ray date (e.g., ulna and radius fractures)
were counted as one fracture event. Nonvertebral fractures
were reported and confirmed as they occurred throughout
FREEDOM and the Extension. Vertebral fractures were con-
firmed from scheduled spine x-rays annually in FREEDOM
and at years 2, 3, 5, and 7 in the Extension (i.e., years 5, 6, 8,
and 10 from FREEDOMbaseline). Clinical vertebral fractures
were also confirmed from unscheduled spine x-rays through-
out FREEDOM and the Extension.
Statistical methods
Subsequent fractures were analyzed as recurrent events using
the stratified Cox and the Prentice-Williams-Petersen total
time models with the robust variance estimation adjusting
for prior fracture. The analysis was repeated in subgroups of
subjects with or without prevalent vertebral fracture, defined
at treatment baseline, without adjusting for prior fracture.
Treatment-by-subgroup interaction was also assessed. Time-
to-first subsequent fracture during treatment was depicted
using the Kaplan-Meier method.
Follow-up for subsequent fractures started from the first in-
cident osteoporotic fracture during treatment through end of
treatment, defined as the earlier of 7 months after the last dose
or the end of study. Fractures after the end of treatment were
excluded. Specifically, in the FREEDOM placebo and
FREEDOMdenosumab groups, follow-up started from the first
incident fracture in FREEDOM through the end of treatment in
FREEDOM (maximum 3 years of follow-up). In the Extension
long-term group, follow-up started from the first incident frac-
ture in FREEDOM or the Extension through the end of treat-
ment in the Extension (maximum 10 years of follow-up). In the
Extension crossover group, follow-up started from the first in-
cident fracture in the Extension through the end of treatment in
the Extension (maximum 7 years of follow-up).
Results
During FREEDOM, 438 placebo- and 272 denosumab-
treated subjects received at least two doses of investigational
product, had an osteoporotic fracture, and remained on study
post-fracture. The mean ages at first on-treatment fracture
were 74.1 and 74.5 years for the placebo- and denosumab-
treated subjects, respectively. Subject characteristics were
generally balanced between the placebo- and denosumab-
treated groups in the FREEDOM 3-year analysis.
After 3 years in FREEDOM, 23 of 3702 subjects (0.6%)
in the denosumab group had multiple new vertebral frac-
tures compared with 59 of 3691 subjects (1.6%) in the pla-
cebo group. The risk ratio (95% confidence interval) for this
reduction in multiple vertebral fractures is 0.39 (0.24, 0.63).
When all subjects on denosumab from FREEDOM and the
Extension for up to 10 years were combined (the combined
denosumab group), 794 had an incident osteoporotic frac-
ture while on denosumab, with a mean age at first incident
fracture of 76.5 years. Other baseline characteristics for
these subjects were similar to those observed in the
FREEDOM 3-year analysis, except the expected longer
treatment duration prior to first fracture and follow-up du-
ration after the first fracture (Table 1).
Table 1 Subject characteristics
FREEDOM analysis (3 years) FREEDOM +
Extension
analysis
(10 years)
Placebo
N = 438
Denosumab
N = 272
Combined
denosumab
N = 794
Age at the beginning
of treatment, years
72.7 (5.3) 73.2 (5.2) 73.2 (5.1)
Age at first incident
fracture, years
74.1 (5.5) 74.5 (5.3) 76.5 (5.3)
Prior osteoporotic
fracture before
treatment, n (%)
255 (58.2) 160 (58.8) 446 (56.2)
Baseline vertebral
fracture before
treatment, n (%)
145 (33.1) 103 (37.9) 261 (32.9)
Total hip BMD
T-score at the be-
ginning of treat-
ment
− 2.2 (0.8) − 2.1 (0.8) − 2.0 (0.8)
Closest total hip BMD
T-score during
treatment prior to
first incident frac-
ture
− 2.1 (0.8) − 1.9 (0.8) − 1.7 (0.9)
Treatment duration
prior to first
incident fracture,
median (Q1, Q3),
years
1.3 (0.8, 2.0) 1.2 (0.6, 2.1) 2.7 (1.2, 5.0)
Follow-up duration
after first incident
fracture, median
(Q1, Q3), years
1.1 (0.6, 2.0) 1.3 (0.6, 2.1) 3.0 (1.5, 5.2)
Data are mean (standard deviation) unless otherwise noted
N subjects who received ≥ 2 doses of investigational product, had an osteo-
porotic fracture on treatment, and remained on study post-fracture, n number
of subjects, BMD bone mineral density, Q1, Q3 quartiles 1 and 3
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Of the placebo- and denosumab-treated subjects with an
incident osteoporotic fracture in FREEDOM, 54 (12.3%)
and 24 (8.8%) subjects, respectively, had one or more subse-
quent fractures in these groups. The exposure-adjusted subse-
quent fracture rate was 10.1 per 100 subject-years for placebo-
treated subjects vs 6.7 per 100 subject-years for denosumab-
treated subjects (Table 2; hazard ratio, HR [95% confidence
interval, CI]: 0.65 [0.41–1.03]; P = 0.0685; Fig. 2). Of the
subjects in the combined denosumab group, one or more sub-
sequent fractures occurred in 144 (18.1%) subjects, with an
exposure-adjusted subsequent fracture rate of 5.8 per 100 sub-
ject-years, similar to the rate observed in the FREEDOM
denosumab group (Table 2). The risk of having a subsequent
on-study osteoporotic fracture was lower in the combined
denosumab group than in the FREEDOM placebo group
(HR 0.59 [95% CI 0.43–0.81]; P = 0.0012; Fig. 2).
The median time to subsequent fracture since the first inci-
dent fracture was 1.0 year for the FREEDOM placebo group,
0.8 years for the FREEDOM denosumab group, and 1.9 years
for the combined denosumab group. The difference between
the time to first subsequent fracture between the combined
denosumab vs placebo group subjects was significant with a
log rank P value = 0.0045; Fig. 3).
A majority of subjects who had subsequent osteoporotic
fractures had only one subsequent fracture: 90.7% (49 of 54
subjects) in the FREEDOM placebo group, 91.7% (22 of 24
subjects) in the FREEDOM denosumab group, and 89.6%
(129 of 144 subjects) in the combined denosumab group.
Vertebral fracture was the most common subsequent fracture
across groups; a greater proportion of subjects in the
FREEDOM placebo group (72.2%; 39 of 54) experienced
these fractures compared with the FREEDOM denosumab
(29.2%; 7 of 24) group and the combined denosumab
(48.6%; 70 of 144) group. The second most common sub-
sequent fracture location was the forearm, sustained by 4
of 54 (7.4%) subjects in the FREEDOM placebo group, 5
of 24 (20.8%) subjects in the FREEDOM denosumab
group, and 29 of 144 (20.1%) subjects in the combined
denosumab group (Table 3).
The effect of denosumab treatment on the reduction of
subsequent fracture risk after an on-study fracture was signif-
icantly greater in subjects with baseline vertebral fractures
compared with subjects without baseline vertebral fracture
(P value = 0.0347). The refracture rate in subjects with base-
line vertebral fracture in the FREEDOM placebo group was
17.4 per 100 subject-years vs 7.8 per 100 subject-years in the
combined denosumab group (HR [95%CI]: 0.41 [0.26–0.65];
p < 0.0001). The refracture rate in subjects without baseline
vertebral fracture in the FREEDOM placebo group was 6.8
per 100 subject-years vs 4.9 per 100 subject-years in the
Table 2 Subsequent osteoporotic fracture rate and time to onset
FREEDOM analysis
(3 years)
FREEDOM + Extension
analysis (10 years)
Placebo
N = 438
Denosumab
N = 272
Combined denosumab N = 794
Subject-years of follow-up 532.3 357.2 2497.5
Subjects with ≥ 1 subsequent fracture, n (%) 54 (12.3) 24 (8.8) 144 (18.1)
Exposure-adjusted subsequent fracture rate, per 100 subject-years 10.1 6.7 5.8
Median time to subsequent fracture since first incident fracture among subjects with
≥ 1 subsequent fracture, years
1.0 0.8 1.9
N subjects who received ≥ 2 doses of investigational product, had an osteoporotic fracture on treatment, and remained on study post-fracture, n number of
subjects
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Fig. 2 Subsequent osteoporotic
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combined denosumab group from the Extension (HR [95%
CI]: 0.81 [0.50–1.30]; P = 0.373; Fig. 4).
Subjects with at least one on-study osteoporotic fracture
event were further analyzed to determine whether there were
any differences in baseline characteristics between subjects
with and without subsequent fractures. Baseline age and age
at first incident fracture were similar between these groups.
Overall, among the subjects who suffered an incident fracture,
those with a subsequent fracture were more likely to have had
a baseline vertebral or osteoporotic fracture than were those
who did not suffer a subsequent fracture (Table 4).
The rates of subsequent vertebral and nonvertebral frac-
tures were also determined for subjects with subsequent
fractures. For subjects with subsequent osteoporotic frac-
tures in the FREEDOM placebo group, 31.5% had both
initial and subsequent vertebral fractures, 7.4% had an ini-
t ia l ver tebral f racture fol lowed by a subsequent
nonvertebral fracture, 40.7% had an initial nonvertebral
fracture followed by a subsequent vertebral fracture, and
20.4% had both initial and subsequent nonvertebral frac-
tures. For subjects with subsequent osteoporotic fractures
in the combined denosumab group, 21.5% had both initial
and subsequent vertebral fractures, 10.4% had an initial
vertebral fracture followed by a subsequent nonvertebral
fracture, 27.1% had an initial nonvertebral fracture followed
by a subsequent vertebral fracture, and 41.0% had both ini-
tial and subsequent nonvertebral fractures (Table 5).
Discussion
In this analysis, refracture rates were lower in subjects who
received denosumab compared with subjects who received
placebo, both among those with and without a baseline
Log-rank p-value (FREEDOM denosumab vs FREEDOM placebo) = 0.1111
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(n = 438)
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(n = 794)Fig. 3 Time to first subsequent
osteoporotic fracture among
subjects in FREEDOM placebo,
FREEDOM denosumab, and
combined denosumab groups
Table 3 Number of subsequent
osteoporotic fractures and fracture
by location
FREEDOM analysis (3 years) FREEDOM + Extension analysis (10 years)
PlaceboN = 54 Denosumab
N = 24
Combined
Denosumab N = 144
Number of subsequent fractures, n (%)
1 49 (90.7) 22 (91.7) 129 (89.6)
2 4 (7.4) 2 (8.3) 14 (9.7)
3 1 (1.9) 0 (0) 1 (0.7)
Subsequent fracture by location, n (%)
Spine 39 (72.2) 7 (29.2) 70 (48.6)
Forearm 4 (7.4) 5 (20.8) 29 (20.1)
Lower leg 2 (3.7) 1 (4.2) 8 (5.6)
Hip 1 (1.9) 3 (12.5) 8 (5.6)
Thorax 3 (5.6) 1 (4.2) 7 (4.9)
Shoulder 2 (3.7) 3 (12.5) 7 (4.9)
Foot 1 (1.9) 2 (8.3) 5 (3.5)
Thigh 0 (0) 1 (4.2) 5 (3.5)
Pelvis 1 (1.9) 1 (4.2) 4 (2.8)
Hand 1 (1.9) 0 (0) 1 (0.7)
N number of subjects who had at least one subsequent osteoporotic fracture, n number of subjects
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vertebral fracture. However, in subjects without baseline ver-
tebral fracture, the size of the denosumab treatment effect was
smaller compared with subjects with baseline vertebral frac-
ture, and it did not reach statistical significance. Of note, in
subjects without prevalent vertebral fracture in FREEDOM,
subjects receiving denosumab had lower fracture rates (1.7%)
compared with subjects receiving placebo (5.2%); risk ratio
(95% confidence interval) 0.31 (0.22, 0.44), indicating that
denosumab is effective in subjects without prevalent vertebral
fracture [17]. These data indicate that subjects with a greater
risk of fracture benefit most from continuous treatment with
denosumab. Fracture risk after an initial fracture event is rel-
atively high, even in subjects receiving denosumab treatment
(6.7 per 100 subject-years in the FREEDOM denosumab and
Subjects With
Baseline Vertebral Fracture
Placebo
(n = 145)
Combined 
Denosumab
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Fig. 4 Exposure-adjusted subject
incidence of subsequent
osteoporotic fracture in subjects
with and without baseline
vertebral fracture
Table 4 Baseline characteristics of subjects with and without subsequent fracture
FREEDOM analysis (3 years) FREEDOM + Extension analysis
(10 years)
Subjects with subsequent fracture Subjects without subsequent fracture Subjects
with subsequent
fracture
Subjects
without subsequent
fracture
Placebo N = 54 Denosumab
N = 24
Placebo N = 384 Denosumab
N = 248
Combined
denosumab
N = 144
Combined
denosumab
N = 650
Age at the beginning of
treatment, years
72.1 (5.4) 73.5 (6.0) 72.8 (5.3) 73.1 (5.1) 73.2 (5.0) 73.2 (5.1)
Age at first incident
fracture, years
73.2 (5.7) 74.7 (6.0) 74.3 (5.4) 74.5 (5.2) 76.1 (5.1) 76.6 (5.4)
Prior osteoporotic
fracture before
treatment, n (%)
45 (83.3) 18 (75.0) 210 (54.7) 142 (57.3) 94 (65.3) 352 (54.2)
Baseline vertebral
fracture before
treatment, n (%)
29 (53.7) 14 (58.3) 116 (30.2) 89 (35.9) 60 (41.7) 201 (30.9)
Total hip BMDT-score at
the beginning of treat-
ment
− 2.34 (0.77) − 2.42 (0.75) − 2.12 (0.81) − 2.09 (0.80) − 2.02 (0.82) − 2.03 (0.82)
Closest total hip BMD
T-score during treat-
ment prior to first in-
cident fracture
− 2.29 (0.84) − 2.43 (0.97) − 2.11 (0.81) − 1.91 (0.81) − 1.74 (0.88) − 1.70 (0.86)
Treatment duration prior
to first incident
fracture, median (Q1,
Q3), years
1.02 (0.52, 1.96) 0.87 (0.54, 1.27) 1.40 (0.84, 2.01) 1.25 (0.66, 2.13) 2.21 (1.01, 4.81) 2.82 (1.26, 5.03)
Data are mean (standard deviation) unless otherwise noted
N subjects who received ≥ 2 doses of investigational product, had an osteoporotic fracture on treatment, and remained on study post-fracture, n number of
subjects, BMD bone mineral density, Q1, Q3 quartiles 1 and 3
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5.8 per 100 subject-years in the combined denosumab groups)
although this risk is lower compared with the FREEDOM
placebo group (10.1 per 100 subject-years). These data give
assurance that, if continuous denosumab treatment is admin-
istered for up to 10 years, the subsequent fracture rate remains
much lower than that observed in subjects not receiving active
treatment after sustaining a fracture. Furthermore, there is ev-
idence that discontinuation of denosumab returns subjects to
their pretreatment fracture risk within a year or two [18, 19].
A persistent question remains in the treatment of osteo-
porosis regarding a comprehensive definition of inadequate
response to therapy and when and whether the term
Btreatment failure^ applies to subjects receiving treatment
for osteoporosis [9–11]. A subject may be considered to
have an inadequate response to therapy if he or she has
one fracture with decreases in BMD or two (or more) frac-
tures. The role of bone remodeling markers and BMD mea-
surements in combination with the number of fractures con-
tributes to an overall assessment of the subject which the
clinician should use in clinical decision making.
Determining when a treatment for osteoporosis is subopti-
mal or inadequate remains a challenge; therefore, an ongoing
evaluation of the efficacy of treatment, including consider-
ation of a change in therapy, should be conducted throughout
the course of treatment. No treatment completely eliminates
fracture risk, and a single fracture in the absence of a decrease
in BMD may not necessarily indicate an inadequate response
to therapy. Unfortunately, it is impossible to know unequivo-
cally whether a treatment is optimal. Clinical judgment of the
treating physician is required in order to determine optimal
future therapy in a subject after an on-treatment fracture event.
In the FREEDOM study, subjects with a baseline vertebral
fracture who suffered an incident fracture were at the highest
risk of subsequent fracture. In this high-risk subgroup, there
was an even greater reduction in on-study subsequent fracture
rates in subjects continuing on, or switching to, denosumab in
the Extension. This suggests that subjects at high risk for
fracture are those who benefit the most from continued treat-
ment with denosumab, likely because of their higher baseline
fracture risk.
Limitations of our study include the generation of data from a
post-hocsubgroupanalysis.Also, theplacebogroupcrossedover
to denosumab therapy after 3 years, leaving no placebo compar-
ator during the Extension study. Follow-up time for the placebo-
treated subjects was therefore limited to a maximum of 3 years,
whereas follow-up time for the combined denosumab subjects
couldbeup to10years.Furthermore, thenumberof subjectswith
subsequent fractures was fairly small, particularly in the
FREEDOM placebo group, which limits the precision of esti-
mates, particularly regarding vertebral vs nonvertebral fracture
rates. Median post-first fracture follow-up duration was longer
in subjects in the FREEDOM denosumab group (1.31 years) vs
subjects in the FREEDOM placebo group (1.06 years), which
changes the baseline characteristics and the length of exposure
to subsequent fracture risk. Finally, 57 subjects (47 placebo-
treated and 10 denosumab-treated) discontinued from the study
(and treatment) at the time of first fracture in FREEDOM. Most
occurred at the end of FREEDOM and were not included due to
lackof follow-up in theFREEDOManalysis.Baseline character-
istics for these subjects were similar, both between treatment
groups and between those who did not discontinue therapy after
first fracture (data not shown).
Our data demonstrate that denosumab decreases the risk of
subsequent fracture, and a fracture sustained while on
denosumab is not necessarily indicative of inadequate re-
sponse to therapy. Continuing denosumab therapy appears to
be a safe and valid clinical option in postmenopausal women
with osteoporosis. These data may help guide clinicians in
choosing the optimal treatment for subjects who have had
fractures while receiving denosumab.
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Table 5 Initial and subsequent
osteoporotic fractures by fracture
type
FREEDOM analysis (3 years) FREEDOM + Extension analysis
(10 years)
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